Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2010

View Archived Issues

GSK-256066 safe and well tolerated in patients with COPD

Auto TAG vaccine shows clinical benefit in advanced cancer

Ad3-hTERT-E1A shows favorable clinical safety in solid tumors

E. coli DH5 alpha-delivered sTRAIL shows promise as solid tumor therapy

Phase IIb safety and efficacy data presented on MP-376 in cystic fibrosis

Phase II data suggest talactoferrin reduces mortality in severe sepsis

High plasma endostatin predicts worse functional outcome in t-PA-treated stroke patients

NovaBay Pharmaceuticals claims new antimicrobial agents

New CXCR7 modulators described by ChemoCentryx

Auspex Pharmaceuticals claims new glucocorticoid receptor modulators

Bayer Schering Pharma discloses new HIF inhibitors

Genzyme discloses achievements of first quarter 2010

Orexo and OMJ join to develop therapeutics for respiratory diseases

EMA considers postapproval commitment fulfilled for Ceplene/IL-2 in AML

Novel FAAH inhibitors presented by sanofi-aventis

Onyx begins phase I trial of oral proteasome inhibitor ONX-0912

Phase II trial of BCX-4208 with or without allopurinol initiated in gout

AstraZeneca receives FDA complete response letters on Axanum and Nexium

CrystalGenomics' phase I trial of CG-200745 approved in Korea

FDA accepts Qnexa NDA for obesity for review

Genfit receives approval for two IT-Diab trials in France

HUYA and BUCM to codevelop therapeutics from traditional Chinese medicine

CF-102 decreases HCV load in patient with liver cancer

Covidien to acquire ev3

FDA grants priority review to eribulin mesilate NDA for breast cancer

Bioheart plans cell therapy program in CHF and PAD in Middle East

Artec reports improvements of Tubercin for HIV/AIDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...